Gao Chang, Li Min, Jiang An-Li, Sun Rui, Jin Hong-Lin, Gui Hua-Wei, Xiao Fei, Ding Xiang-Wu, Fu Zhen-Ming, Feng Jue-Ping
Department of Oncology, PuAi Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430034, P.R. China.
Department of Clinical Medicine, Medical College, Wuhan University of Science and Technology, Wuhan, Hubei 430065, P.R. China.
Oncol Lett. 2018 Apr;15(4):5451-5458. doi: 10.3892/ol.2018.8042. Epub 2018 Feb 13.
Tumor necrosis factor receptor-associated protein-1 (TRAP-1), a mitochondrial chaperone, contributes significantly to the progression of cancer. However, the understanding of its involvement in the clinicopathological characteristics and prognosis of colorectal cancer (CRC) remains limited. The aim of the present study was to assess the significance of TRAP-1 expression in CRC. The expression of TRAP-1 was evaluated in corresponding cancerous, paracancerous, lymph node and distant metastatic tissues of 256 cases of CRC by immunohistochemistry. The associations between TRAP-1 expression and the clinicopathological parameters and survival rates of patients was assessed. Out of 256 patients with CRC, TRAP-1 expression was detected in 203 (79.3%). TRAP-1 expression was significantly increased in cancerous tissue compared with that in corresponding paracancerous tissues (P<0.001). Overexpression of TRAP-1 was significantly associated with differentiation (P=0.011), depth of invasion (P=0.006), lymph node metastasis (P<0.001) and tumor-node-metastasis stage (P<0.001). In patients with high TRAP-1 expression, the 5-year overall survival (OS) rate was 38.0%, in contrast to 56.5% in patients with low TRAP-1 expression (P=0.003). Similarly, the 5-year progression-free survival (PFS) was 26.6% for patients with high TRAP-1 expression and 53.3% for patients with low TRAP-1 expression (P<0.001). Multivariate analyses indicated the TRAP-1 expression is an independent prognostic factor for poorer OS [P=0.015; hazard ratio (HR), 1.914] and PFS (P<0.001; HR, 2.534). Thus, TRAP-1 may serve as a potential biomarker for predicting the prognosis of patients with CRC. Specifically, overexpression of TRAP-1 may predict progression and poor survival in cases of CRC.
肿瘤坏死因子受体相关蛋白-1（TRAP-1）是一种线粒体伴侣蛋白，对癌症进展有显著影响。然而，其在结直肠癌（CRC）临床病理特征及预后方面的作用仍了解有限。本研究旨在评估TRAP-1表达在CRC中的意义。采用免疫组织化学法检测了256例CRC患者相应癌组织、癌旁组织、淋巴结及远处转移组织中TRAP-1的表达情况。评估了TRAP-1表达与患者临床病理参数及生存率之间的关联。256例CRC患者中，203例（79.3%）检测到TRAP-1表达。与相应癌旁组织相比，癌组织中TRAP-1表达显著升高（P<0.001）。TRAP-1过表达与分化程度（P=0.011）、浸润深度（P=0.006）、淋巴结转移（P<0.001）及肿瘤-淋巴结-转移分期（P<0.001）显著相关。TRAP-1高表达患者的5年总生存率（OS）为38.0%，而TRAP-1低表达患者为56.5%（P=0.003）。同样，TRAP-1高表达患者的5年无进展生存率（PFS）为26.6%，低表达患者为53.3%（P<0.001）。多因素分析表明，TRAP-1表达是OS较差（P=0.015；风险比[HR]，1.914）和PFS较差（P<0.001；HR，2.534）的独立预后因素。因此，TRAP-1可能作为预测CRC患者预后的潜在生物标志物。具体而言，TRAP-1过表达可能预示CRC患者病情进展及预后不良。
